摘要
目的:探究脑脉利颗粒对糖尿病性视网膜病变的治疗效果及作用机制。方法:应用高浓度葡萄糖诱导野生型斑马鱼、转基因型血管内皮细胞增强型绿色荧光蛋白标记(flil:EGFP)斑马鱼和转基因型中性粒细胞增强型绿色荧光蛋白标记(mpx:EGFP)斑马鱼糖尿病性视网膜病变模型,并进行给药,在6 dpf时,通过体视显微镜和qPCR等方法检测斑马鱼体内葡萄糖水平、眼睛大小、视网膜血管直径、炎症程度(IL-1β、IL-6、TNF-α)、NO和CTGF水平。结果:与对照组比较,模型组斑马鱼视网膜血管直径增大(P<0.05),体内血糖浓度、血管中中性粒细胞数量、CTGF mRNA、IL-1β mRNA、IL-6 mRNA、TNF-α mRNA、NO水平均明显升高(P<0.05)。与模型组比较,复方血栓通胶囊低、高剂量组和脑脉利颗粒低、中、高剂量组斑马鱼视网膜血管直径减小(P<0.05),体内血糖浓度、血管中中性粒细胞数量、CTGF mRNA、IL-1βmRNA、IL-6 mRNA、TNF-α mRNA、NO水平均明显降低(P<0.05)。结论:脑脉利颗粒对斑马鱼糖尿病性视网膜病变模型有治疗作用,这种治疗作用可能是通过降低血糖、减轻视网膜微血管病变、降低体内炎症水平等机制来发挥作用的。
Objective:To study the therapeutic effect and mechanism of action of Naomaili Granules on diabetic retinopathy.Methods:The diabetes retinopathy model of wild zebrafish,transgenic vascular endothelial cell enhanced green fluorescent protein(flil:EGFP)zebrafish and transgenic neutrophil enhanced green fluorescent protein(mpx:EGFP)zebrafish was induced by high concentration glucose and administered.At 6 DPF,the levels of glucose,eye size,retinal vessel diameter,degree of inflammation(IL1β,IL6,TNF-α),NO and CTGF level in zebrafish were detected by stereomicroscope and qPCR.Results:Compared with the control group,the retinal vessel diameter of zebrafish in the model group increased(P<0.05),and the blood glucose concentration,the number of neutrophils in blood vessels,and the levels of CTGF mRNA,IL-1β mRNA,IL-6 mRNA,TNF-α mRNA,and NO were significantly increased(P<0.05).Compared with the model group,the retinal vessel diameter of zebrafish in the low and high dose groups of Fufang Xueshuantong Capsule(复方血栓通胶囊)and the low,medium and high dose groups of Naomaili Granule were decreased(P<0.05),and the blood glucose concentration,the number of neutrophils in blood vessels,the levels of CTGF mRNA,IL-1β mRNA,IL-6 mRNA,TNF-α mRNA,and NO were decreased significantly(P<0.05).Conclusion:Naomaili Granule has therapeutic effect on zebrafish diabetes retinopathy model.It may be exerted through lowering blood glucose,ameliorate retinal microangiopathy,reduce inflammation levels and other mechanisms to exert the effect.
作者
苏梅
娄雅静
王姗
李双利
秦引林
SU Mei;LOU Yajing;WANG Shan;LI Shuangli;QIN Yinlin(Jiangsu Carephar Pharmaceutical Co.,Ltd,Nanjing Jiangsu 210016,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing Jiangsu 210009,China)
出处
《中医药导报》
2022年第6期24-29,共6页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
